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The causal relevance of body mass 
index in different histological 
types of lung cancer: A Mendelian 
randomization study
Robert Carreras-Torres1, Philip C. Haycock2, Caroline L. Relton2, Richard M. Martin2,3, 
George Davey Smith2, Peter Kraft4, Chi Gao4, Shelley Tworoger4,5, Loïc Le Marchand6, 
Lynne R. Wilkens6, Sungshim L. Park7, Christopher Haiman7, John K. Field8, Michael Davies8, 
Michael Marcus8, Geoffrey Liu9, Neil E. Caporaso10, David C. Christiani11, Yongyue Wei11, 
Chu Chen12, Jennifer A. Doherty13, Gianluca Severi14, Gary E. Goodman15, Rayjean J. Hung16, 
Christopher I. Amos17, James McKay1, Mattias Johansson1 & Paul Brennan1
Body mass index (BMI) is inversely associated with lung cancer risk in observational studies, even 
though it increases the risk of several other cancers, which could indicate confounding by tobacco 
smoking or reverse causality. We used the two-sample Mendelian randomization (MR) approach to 
circumvent these limitations of observational epidemiology by constructing a genetic instrument 
for BMI, based on results from the GIANT consortium, which was evaluated in relation to lung cancer 
risk using GWAS results on 16,572 lung cancer cases and 21,480 controls. Results were stratified 
by histological subtype, smoking status and sex. An increase of one standard deviation (SD) in BMI 
(4.65 Kg/m2) raised the risk for lung cancer overall (OR = 1.13; P = 0.10). This was driven by associations 
with squamous cell (SQ) carcinoma (OR = 1.45; P = 1.2 × 10−3) and small cell (SC) carcinoma (OR = 1.81; 
P = 0.01). An inverse trend was seen for adenocarcinoma (AD) (OR = 0.82; P = 0.06). In stratified 
analyses, a 1 SD increase in BMI was inversely associated with overall lung cancer in never smokers 
(OR = 0.50; P = 0.02). These results indicate that higher BMI may increase the risk of certain types of 
lung cancer, in particular SQ and SC carcinoma.
Obesity increases the risk of many chronic diseases, including several cancers1, although observational studies 
have indicated an inverse relationship between body mass index (BMI), the most commonly used measure of 
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obesity, and lung cancer risk, in particular among former and current smokers2–8. These associations may be due 
to a number of factors, in particular reverse causation (preclinical disease leading to weight loss). Smoking is also 
thought to reduce body weight, and residual confounding by tobacco smoking is another possible explanation 
for this inverse association. Given the strong increased risk of lung cancer caused by tobacco exposure and the 
well described association between tobacco consumption and reduced body weight9–11, traditional observational 
studies are unlikely to be able to fully account for the confounding effect of tobacco exposure when describing the 
relationship between BMI and lung cancer risk9–11.
Genetic epidemiology can circumvent some of the inherent limitations of observational epidemiology by 
modeling non-genetic risk factors using genetic instruments, and evaluating the association between the genetic 
instrument and disease risk rather than between the modifiable factor and disease risk. Germline gene variants 
are not affected by the presence of undiagnosed disease or associated with confounding exposures. Therefore, this 
technique, commonly referred to as Mendelian randomization (MR)12, is considered less sensitive to some of the 
biases that afflict traditional observational epidemiology13, in particular reverse causality and residual confound-
ing. Our study utilized ‘two-sample Mendelian randomization’ to clarify the causal relationship between obesity 
and lung cancer risk, by constructing a genetic instrument for BMI in one study population, and subsequently 
evaluating the association of that genetic instrument with lung cancer risk in a large genome wide association 
study (GWAS)13.
Materials and Methods
Genetic instruments for BMI. Genetic instruments for BMI were identified using results from the Genetic 
Investigation of ANthropometric Traits (GIANT) consortium, a large collaborative GWAS on human body size 
and shape. Using GWA data on 339,224 individuals14, GIANT identified 97 single nucleotide polymorphisms 
(SNPs) independently (linkage disequilibrium R2 < 0.1) associated with BMI at a genome-wide significance level. 
In the GIANT study population, these 97 SNPs explained 2.7% of in-study variance in BMI. For each of the 97 
SNPs, we retrieved the effect estimate that was expressed in standard deviations (SD) of BMI (SD change in BMI 
per-allele, β GP), along with the relevant standard error from the consortium website, and coded each SNP so that 
the reference allele was associated with an increase in BMI15. In the GIANT study population, 1 SD change in 
BMI equaled 4.65 kg/m2.
Lung cancer, phenotypic BMI and tobacco related data. Summary statistics on lung cancer risk, 
including OR estimates and standard errors for instrumental SNPs, were available from the Transdisciplinary 
Research In Cancer of the Lung (TRICL) and International Lung Cancer Consortium (ILCCO)16 based on 4 lung 
cancer GWAS with a total of 11,348 lung cancer cases and 15,861 controls. Individual level data were available 
from three sources, i) a subset of the TRICL GWAS including 2,554 lung cancer cases and 3,825 controls from the 
International Agency for Research on Cancer-ILCCO sample (IARC-ILCCO)16, ii) 1,437 lung cancer cases and 
1,453 controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) study17 who had 
been genotyped using the GAME-ON OncoArray18, and iii) 3,456 lung cancer cases and 3,850 controls based on 7 
studies genotyped using a custom Affymetrix Axiom Array (Affymetrix, Santa Clara, CA, USA)19. Only European 
descent subjects were included in the study. Each study has been specifically approved by the Ethical Committees 
of the original studies and all the participants provided a written informed consent. Covariates available from the 
IARC-ILCCO, EPIC, and Axiom data (namely measured BMI, smoking status, cigarettes per day, and additional 
measures of historical smoking exposure such as pack-years) were used to validate the genetic instrument based 
on the GIANT study, as well as to evaluate if the BMI genetic instrument was associated with measures of tobacco 
exposure. All genome-wide studies were imputed using the 1000 Genomes Project ALL panel (Phase I integrated 
Release 3) in the original projects. Imputation quality parameters were checked in each lung cancer sample for 
the 97 BMI-instrumental SNPs, and only SNPs with imputation quality higher than 0.6 were selected for the 
Mendelian randomization analyses.
Statistical methods. To evaluate the validity of the genetic instruments, we initially constructed a genetic 
score for BMI with individual allele dosages weighted by the estimated per-allele effect on BMI (β GP) as provided 
by the GIANT consortium14. The association between the BMI genetic score and measured BMI was subse-
quently evaluated in each of the studies where individual level data were available. We similarly evaluated the 
association between the BMI instrument and measures of tobacco exposure (cigarettes per day (CPD), cotinine 
levels, and pack-years (PY)). These relationships were modeled using linear regression, controlling for age, sex 
and principal components to account for population stratification. Pooled estimates of the association between 
BMI genetic score and the tested BMI and smoking phenotypes were obtained by fixed-effects meta-analysis 
using the metagen R package, and I2 statistic to quantify the proportion of the total variation due to heterogeneity 
were calculated. Additionally, power calculations for the MR analysis were performed acording to Burgess20, 
assuming a nominal statistical significance of alpha 0.05 and a genetic instrument explaining 2.7% of phenotype 
variance14.
To evaluate the association between the BMI instrument and lung cancer risk, SNP to disease effects (β GD) 
were obtained by meta-analyses of the different study effect estimates using the METAL software21. The overall 
causal effect of BMI on lung cancer risk was subsequently estimated using a likelihood-based approach22. Since 
the BMI instrument was calibrated in units of SD of BMI (4.65 kg/m2 in the GIANT consortium), the resulting 
OR and 95% confidence interval provide an estimate of relative risk of lung cancer caused by a one SD increase 
in BMI.
To evaluate the extent to which the risk estimates may be driven by pleiotropy, we re-evaluated the associa-
tion between the BMI instrument after excluding the rs11030104 SNP which was reported to be associated with 
smoking initiation by the GIANT consortium14. In addition, we used two complementary approaches: sensitivity 
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analyses for the likelihood approach to possible departures of the main assumption of an absence of pleiotropy, 
namely the weighted median estimator23 and the MR-Egger approach24. The weighted median estimator is the 
median of a distribution in which Wald ratio estimates (β GD/β GP) have been ordered and represent percentiles of 
this distribution. The percentile which each ratio estimate represents is given by a weighting formula as a function 
of the standardized inversed variance of the ratio estimates23. The MR-Egger approach performs a weighted linear 
regression of the SNP to disease effects (β GD) on the SNP to phenotype effects (β GP), giving evidence for potential 
overall directional pleiotropy24.
Results
Analyzed samples. The total sample, with available GWAS data or summary risk association estimates, 
comprised 21,480 controls and 16,572 lung cancer cases overall. From those cases with histology information 
available, there were 5,282 adenocarcinoma (AD), 4,224 squamous cell (SQ) and 904 small cell (SC) cases. For 
samples with individual level data, the proportion of ever smokers among control groups ranged from 65 to 68%, 
while among the cases the rates were higher, between 89 and 94%. Within histology groups, AD cases presented 
lower proportions of ever smokers (82–86%) compared with SQ and SC cases (96–98%). Likewise, the distribu-
tion of sex was not uniform among histological groups. The proportion of males in AD cases ranged from 43 to 
64%, while in SQ and SC cases the range was between 52 and 87% (Supplementary Table S1). After excluding 
SNPs with low imputation quality, the number of contributing SNPs was 92 for TRICL and IARC-ILCCO, 96 
for EPIC and 65 for Axiom data sets. Further information on each of the 97 SNPs is presented in Supplementary 
Tables S2–S5.
Validation of BMI instrument. The BMI instrument was associated with measured BMI in our study sam-
ple (Change in BMI kg/m2 per unit of the genetic score [95%CI] = 3.27 [2.70–3.84]; P < 1.0 × 10−17), and was 
not associated with available measures of tobacco exposure (P > 0.19), including pack years, cigarettes per day 
(CPD) or cotinine levels (Fig. 1). Association results within each study for the BMI score instrumental validation 
are shown in Supplementary Table S6. Power calculations indicated that our sample provided sufficient statistical 
power (80%) to detect an OR of 1.21 for overall lung cancer, 1.32 for adenocarcinoma, 1.36 for squamous cell car-
cinoma, 1.85 for small cell carcinoma, 1.36 for lung cancer overall ever smokers, and 2.14 for lung cancer overall 
never smokers (Supplementary Fig. S1).
BMI causal effect estimation using a likelihood-based MR approach. The genetic instrument 
for BMI was positively associated with overall lung cancer risk: the estimated OR per genetically elevated one 
SD increase in BMI was 1.13 ([95%CI] = [0.98–1.30], P = 0.10). In analyses stratified by histology, the asso-
ciation between the BMI genetic instrument and risk was evident for SQ carcinoma (OR [95%CI] = 1.45 
[1.16–1.62]; P = 1.19 × 10−3) and for SC carcinoma (OR [95%CI] = 1.81 [1.14–2.88]; P = 0.01), but not for 
AD (OR [95%CI] = 0.82 [0.66–1.01]; P = 0.06) (P value of heterogeneity among histological strata = 3 × 10−5) 
(Fig. 2). In the sample subset for which individual level data were available, smoking and sex stratified anal-
ysis were performed only for lung cancer overall due to the limited number of never smokers and the lack of 
power within histological types. The BMI instrument was inversely associated with overall lung cancer in never 
smokers (OR [95%CI] = 0.50 [0.28–0.89]; P = 0.02), while it remained positively correlated in ever smokers 
(OR [95%CI] = 1.10 [0.87–1.39]; P = 0.44) (P value of heterogeneity between never and ever smokers in over-
all = 0.01) (Fig. 2). In sex stratified analyses, no differences were observed between sex groups (P value of het-
erogeneity = 0.28). Meta-analysis results for the 97 SNPs (β GD) on the described phenotypes are presented in 
Supplementary Table S7.
Figure 1. Forest plot of association analyses between genetic BMI score and measured BMI, pack years, 
and cigarettes per day (CPD) in the whole sample and within cases and controls. Cotinine levels are shown 
in Supplementary Table S6. 95%CI: 95% Confidence Interval; P: P value. I2: Heterogeneity coefficient.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:31121 | DOI: 10.1038/srep31121
Sensitivity analyses. To evaluate the potential effect of pleiotropy on the causal effect estimates, several 
sensitivity analyses were performed. The first sensitivity analysis was the re-evaluation of the likelihood-based 
approach by removing the rs11030104 SNP (reported to be associated with smoking initiation), which did not 
notably alter the results (Supplementary Table S8). The weighted median analysis resulted in similar risk estimates, 
except for SC carcinoma which was attenuated (OR of 1.42 ([95%CI] = 0.66–3.06; P = 0.37)) (Supplementary 
Table S9). Finally, the analyses of the MR-Egger test did not detect directional pleiotropy effecting risk estimations 
(Supplementary Table S10).
Discussion
This study aimed to evaluate whether Mendelian randomization can help to clarify the causal relationship 
between BMI and lung cancer risk. Large-scale GWAS initiatives provided an informative genetic instrument 
for BMI which was used in subsequent risk analysis in large numbers of lung cancer cases and control. Our 
results suggest that obesity may cause a higher risk of SQ and SC lung carcinoma. The absence of any association 
between our genetic instrument for BMI and smoking patterns suggests that these results are not explained by 
confounding by tobacco. These results are in stark contrast with most observational analyses indicating an inverse 
association between BMI and lung cancer risk.
Several assumptions are required for Mendelian randomization to provide consistent estimates of the 
causal effect of a putative risk factor on diseases, including a sufficiently strong association between the genetic 
instrument and exposure, and the absence of pleiotropy. Two main features of the Mendelian randomization 
methodologies we used to ensure that our results satisfy these assumptions or are robust to deviations from the 
assumptions. First of all, several genetic variants were interrogated as genetic instruments for the modifiable 
exposure at the same time, which reduces the probability of violating the conditions of the methodology regard-
ing true association and pleiotropy-driven bias. Then, the two-sample Mendelian randomization approach22 
allowed us to obtain the calibrated genetic effects from the largest existing genome-wide studies on obesity 
(GIANT consortium with 339,224 participants) and on lung cancer (TRICL, Epic and Axiom datasets with 16,572 
cases and 21,480 controls).
The initial Mendelian randomization approach and subsequent sensitivity analyses showed a consistent risk 
effect of BMI for SQ and SC lung carcinoma subtypes. For the SQ subtype, a 1 SD increase in BMI (4.65 Kg/m2) 
conferred a 45% increased risk of lung cancer. In the case of SC carcinoma, the increase of risk was approximately 
80%, higher than other histological subtypes. Despite the fact that our SC sample had power to detect a risk 
increase of 85%, the 1.81 risk increase detected is still sufficiently powered (77.4%) to consider this as a robust 
result. There was no evidence of any pleiotropic effects on the relative risk estimations. These results, together 
with the suggestive inverse effect for AD, could reflect different contributions of adiposity on each lung cancer 
subtype. Additionally, the analyses stratified by smoking status revealed an inverse association of genetically 
instrumented BMI in never smokers for overall lung cancer reducing the risk by as much as half. However, the 
analysis in never smokers could be slightly underpowered (72.4% of power to detect a risk of 2.0). Finally, a spe-
cific role of BMI regarding sex did not seem to be consistent.
Different hypotheses have been suggested as biological mechanisms for an association between obesity and 
cancer risk in general25. These include mechanisms involving sex hormone metabolism, insulin and insulin-like 
growth factor signaling, and adipokine pathophysiology25. In the case of lung cancer, sex hormone metabolism 
might not be influencing risk since no different effect have been observed regarding sex in this study, as well as 
other observational studies3. At the same time, a potential protective role of BMI on DNA damage from smoking 
or occupational exposures have been observed6. All of these elements point towards diverse and tissue-specific 
mechanisms rather than global systemic physiological explanation.
Our Mendelian randomization study does not support previous results from observational studies that obesity 
may decrease lung cancer risk overall. In contrast, our data indicate that obesity may cause an increased risk of 
SQ and SC lung carcinoma but not of AD.
Figure 2. Forest plot of lung cancer risk for an increase of 1 SD of BMI (approximately 4.65 Kg/m2) observed 
in a likelihood-based MR approach. AD: Adenocarcinoma; SQ: squamous cell lung cancer; SC: small cell lung 
cancer; OR: Odds Ratio; 95%CI: 95% Confidence Interval; P: P value; P Het: P value of heterogeneity among 
individual SNP causal estimates.
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